Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518315

— · F

f62546d0-a687-5bb2-8d0d-0c3f6131d101

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.580
  • ANGIOGENESIS+0.470
  • ANDROGEN_RESPONSE+0.450
  • ADIPOGENESIS+0.440
  • XENOBIOTIC_METABOLISM+0.430
  • OXIDATIVE_PHOSPHORYLATION+0.400
  • COAGULATION+0.380
  • FATTY_ACID_METABOLISM+0.370
  • BILE_ACID_METABOLISM+0.360
  • PROTEIN_SECRETION+0.360

Top 10 suppressed

  • G2M_CHECKPOINT-0.510
  • E2F_TARGETS-0.490
  • MYC_TARGETS_V2-0.420
  • WNT_BETA_CATENIN_SIGNALING-0.410
  • INTERFERON_ALPHA_RESPONSE-0.330
  • MITOTIC_SPINDLE-0.300
  • INTERFERON_GAMMA_RESPONSE-0.280
  • MYC_TARGETS_V1-0.260
  • SPERMATOGENESIS-0.250
  • IL6_JAK_STAT3_SIGNALING-0.240

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518325
breast-umap@18
—F0.953
2SRR8518181
breast-umap@18
—F0.907
320040010.TNBC
breast-umap@18
—F0.879
4TCGA-CN-4726-01A-01R-1436-07
head-neck@1
——0.869
5SRR8518146
breast-umap@18
—F0.861
620060030.TNBC
breast-umap@18
—F0.861
7MNG329
mng-umap@100
——0.835
8SRR8518340
breast-umap@18
—F0.822
9SRR8518149
breast-umap@18
—F0.821
10TCGA-AN-A03X-01A-21R-A00Z-07
breast-umap@18
—A0.821

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.580Inavolisib— uncovered
ANGIOGENESIS0.470Remibrutinib— uncovered
ANDROGEN_RESPONSE0.450Inavolisib— uncovered
ADIPOGENESIS0.440Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.430Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
COAGULATION0.380Binimetinib— uncovered
FATTY_ACID_METABOLISM0.370Inavolisib— uncovered
BILE_ACID_METABOLISM0.360Inavolisib— uncovered
PROTEIN_SECRETION0.360Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.360Inavolisib— uncovered
PEROXISOME0.340Idelalisib— uncovered
MTORC1_SIGNALING0.330Inavolisib— uncovered
GLYCOLYSIS0.290Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.260Remibrutinib— uncovered
HYPOXIA0.240Idelalisib— uncovered
PANCREAS_BETA_CELLS0.230Cobimetinib— uncovered
UV_RESPONSE_DN0.230Inavolisib— uncovered
APOPTOSIS0.210Idelalisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered